Study summary · 2022 · Evidence review

Economic evaluations of RPM across chronic diseases

Economic value depended on the condition, delivery costs, perspective and local willingness to pay.

Summary by Vironix Health · Source review: November 11, 2026
How we select and interpret evidence

Original publication

Economic Evaluations of Remote Patient Monitoring for Chronic Disease: A Systematic Review

Keshia R De Guzman; Centaine L Snoswell; Monica L Taylor; Leonard C Gray; Liam J Caffery

Centre for Online Health and Centre for Health Services Research, University of Queensland, Australia

Value in Health · Online: · Issue: June 2022

Journal version of record. · Full text consulted.

What was studied

Design
Evidence review
Population
People with chronic diseases
Sample
34 economic evaluations
Intervention
Non-invasive RPM
Comparator
Usual care
Follow-up
Economic horizons varied
Review search cutoff
2021-09
Setting
Multiple countries

Methods

Systematic review of economic evaluations; CHEERS assessed reporting completeness, not freedom from model bias.

Findings

Hypertension evaluations generally favored RPM. Heart-failure and COPD conclusions varied by setting and disease severity; diabetes evidence was limited.

Limitations

Heterogeneity prevented meta-analysis. Publication bias and incomplete capital-cost or payback reporting limit transferability.

What this means for care delivery

Cost-effectiveness can coexist with higher spending; calculate local staffing, setup and ongoing costs before projecting savings.